Open Nav

Please submit your session questions in advance at

Sensei Biotherapeutics

  • John Celebi, Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics is an innovator in the field of next-generation cancer immunotherapies, including cancer vaccines and T-cell therapies. We are pioneering the development of precision therapeutics that target ASPH, a powerful, uniquely human, tumor-specific antigen to treat cancer. SNS-301, our lead program, is a first-in-class cancer immunotherapy and has successfully completed a Phase 1 clinical study with plans for further clinical development in hematological malignancies and solid tumors.

  • Date:Monday, February 11
  • Time:3:45 PM - 4:00 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23570
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Pipeline and technology overview
  • Company
  • Company HQ City:Gaithersburg
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$55M
  • Size of Last Investment Round:$20M
  • Previous and Current Investors:H&S Ventures, MedImmune
  • CEO/Top Company Official:John Celebi
  • Year Founded:2015
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:SNS-301 - ASPH targeted genetically engineered vaccine
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
John Celebi
Sensei Biotherapeutics, Inc.